AUS
NZ
UK
CA
USA
IND
Highlights
Smith & Nephew announces the appointment of Dr Garheng Kong as Independent Non-Executive Director
Appointment effective from the beginning of September, with a role on the Audit Committee
Dr Kong brings broad experience in medical technology, biopharma, and investment leadership
Smith & Nephew (LSE:SN), a leading global medical technology organisation, confirmed that Dr Garheng Kong will join the Board as an Independent Non-Executive Director. The appointment will become effective in the first days of September, with Dr Kong also taking on responsibilities as a member of the Audit Committee. This update reflects the company’s commitment to enhancing governance with senior leadership bringing extensive industry experience.
Professional Background of Dr Garheng Kong
Dr Kong is managing partner and co-founder of HealthQuest Capital, a healthcare-focused investment firm. He serves as lead independent director at Laboratory Corporation of America and as a non-executive director for companies including Xeris Biopharma Holdings Inc, Lunit Inc, and IKS Health. His earlier career includes serving as managing general partner at Sofinnova Investments, Inc. Additionally, Dr Kong has held directorships at Venus Concept Inc, Alimera Sciences, Avedro Inc, and acted as chair of Histogenics Corporation.
Chair’s Statement
Rupert Soames, Chair of Smith+Nephew, welcomed the appointment, noting Dr Kong’s strong track record in the medtech and biopharma fields. His broad technical expertise, clinical background, and strategic leadership across numerous organisations were highlighted as strengths that will contribute to Smith+Nephew’s ongoing growth and innovation agenda.
Company Profile
Smith+Nephew operates as a portfolio medical technology business focused on developing and delivering solutions for the repair, regeneration, and replacement of soft and hard tissue. Its purpose, known as “Life Unlimited,” is centered on restoring physical ability and confidence for patients worldwide. With a workforce exceeding seventeen thousand employees, the company operates in about one hundred countries, offering a diverse product portfolio across three global units: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management.
Founded in Hull, United Kingdom, in the nineteenth century, Smith+Nephew has expanded into a multinational enterprise while retaining its focus on healthcare innovation. In the most recent financial year, the organisation reported. The company is listed on the London Stock Exchange under the ticker LON:SN and is also a constituent of the FTSE 350 today, underlining its standing within the UK’s most significant listed businesses.
Market and Regulatory Position
The announcement confirms that no additional disclosure obligations arise under UK Listing Authority rules relating to the appointment. Smith+Nephew continues to operate under the governance standards expected of a major listed company. The business maintains its strong presence within the FTSE index and continues to expand its global impact across healthcare markets.
Contact Information
Investor and analyst enquiries are handled by Cora McCallum at Smith+Nephew, while media enquiries may be directed to Charles Reynolds of Smith+Nephew. Additional media support is provided by Brunswick, with contacts Susan Gilchrist and Ayesha Bharmal available for communications.
Forward-Looking Statements
The company noted that its official communication may include forward-looking information relating to areas such as revenue growth, product pipeline, and operational performance. It emphasised that such statements are subject to external factors including economic conditions, regulatory approvals, technological developments, and supply chain stability. Smith+Nephew reiterated that any such statements are based on information available at the date of issue and that no obligation exists to update these statements in the future.
